Antipsychotic Drugs and Cognitive Function

作者：Lena Feber, Natalie Peter, Virginia Chiocchia, Johannes Schneider‐Thoma, Spyridon Siafis, Irene Bighelli, Wulf‐Peter Hansen, Xiao Lin, Daniel Prates-Baldez, Georgia Salanti, Richard S.E. Keefe, Rolf R. Engel, Stefan Leucht · 发表于：JAMA Psychiatry · 年份：2024 · DOI：10.1001/jamapsychiatry.2024.2890 · 被引用次数：93 · 研究领域：Schizophrenia research and treatment、Treatment of Major Depression、Mental Health and Psychiatry

Importance: Cognitive deficits are a substantial part of the symptoms of schizophrenia spectrum disorders (SSDs) and contribute heavily to the burden of disease. Antipsychotic drugs are not cognitive enhancers, but due to their different receptor-binding profiles, they could differ in their effects on cognition. No previous network meta-analysis compared antipsychotics to placebo, which is important to determine whether use of these drugs is associated with cognitive performance in SSDs at all. Objective: To determine the association of treatment with various antipsychotics and cognition in patients with SSDs. Data Sources: Cochrane Schizophrenia Trials Register through June 25, 2023. Study Selection: Randomized clinical trials examining the effects on cognition of antipsychotic drugs or placebo in participants with SSD. Data Extraction and Synthesis: A systematic review and random-effects frequentist network meta-analysis was performed following Preferred Reporting Items for Systematic Reviews and Meta-analyses-Network Meta-analysis reporting guideline. Main Outcomes and Measures: The primary outcome was change in overall cognition score calculated for each study. Secondary outcomes included cognitive domains, quality of life, and functioning. Results: This study included 68 studies involving 9525 participants (mean [SD] age, 35.1 [8.9] years; 5878 male [70%] and 2890 [30%] female; some studies did not provide this information). There were few clear differences between antip...